Numbers tell the story in psychiatric disease drug development: almost 300 recognized indications,
28% 12-month prevalence that yields large patient populations, strong 7.5% annual sales growth in
recent years, sustained franchise sales, tolerance for use of multiple drugs within a drug class, and
a clinical pipeline of more than 150 agents. Given the heterogeneity of the patient populations in the
psychiatric disease sector, unmet need and commercial opportunity are high. We explore ways in
which companies are using strategic differentiation and novel targets to overcome challenges and tap
sales potential.
Scope
2008 market: 2008 sales; leading drug classes; market-leading companies; commercial
position of leading agents.
Psychiatric disease pipeline: number of agents in development; disease focus; active
companies; profi les of GSK and AZ; mechanisms of action; company type; phase analysis;
novel formulations versus reformulations.
Psychiatric diseases focused on in this report: schizophrenia; depression; anxiety;
(0 items)
